EGFR and non-small cell lung carcinoma: While tyrosine kinase inhibitors (TKIs) like gefitinib are the mainstay treatment for NSCLC patients with epidermal growth factor receptor (EGFR) amplification or sensitive mutations, the majority inevitably encounter disease progression as a result of acquired resistance to these agents.